Baseline Characteristics of Study Population
| Characteristic | Value |
| Mean age (y) | 63.2 (range, 46–77) |
| Clinical T-stage (n) | |
| T1c | 1 (1) |
| T2 | 2 (1.9) |
| T2a | 7 (6.7) |
| T2b | 32 (30.5) |
| T2c | 20 (19) |
| T3 | 4 (3.8) |
| T3a | 29 (27.6) |
| T3b | 10 (9.5) |
| Race (n) | |
| White | 102 (97.1) |
| Black | 2 (1.9) |
| Asian | 1 (1) |
| Mean prostate-specific antigen (ng/mL) | 27.0 (range, 2.4–372.7) |
| Prostate-specific antigen (n) | |
| ≤20 | 68 (65) |
| 2 | 36 (35) |
| Mean GS | 8 (range, 6–9) |
| Biopsy GS (n) | |
| ≤6 | 5 (5) |
| 7 | 41 (39) |
| ≥8 | 59 (56) |
| Enrollment patients (n) | |
| United States | 40 (38) |
| Europe | 65 (63) |
| Ongoing ADT (n) | 20 |
Data in parentheses are percentages unless otherwise indicated.